|
L-Carnitine to Treat Fatigue in AIDS Patients Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on L-Carnitine to Treat Fatigue in AIDS Patients conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. L-Carnitine to Treat Fatigue in AIDS Patients Clinical research trials and L-Carnitine to Treat Fatigue in AIDS Patients health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like L-Carnitine to Treat Fatigue in AIDS Patients. L-Carnitine to Treat Fatigue in AIDS Patients Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a L-Carnitine to Treat Fatigue in AIDS Patients clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their L-Carnitine to Treat Fatigue in AIDS Patients condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > L-Carnitine to Treat Fatigue in AIDS Patients  L-Carnitine to Treat Fatigue in AIDS Patients
L-Carnitine to Treat Fatigue in AIDS Patients
For Condition: HIV Infections,AIDS
Status: Recruiting
Sponsor(s): National Institute of Nursing Research (NINR) ,
Synopsis: Patients with AIDS may develop a deficiency of the micronutrient carnitine and such a deficiency may contribute to fatigue in these patients. This study will determine whether carnitine supplementation will improve fatigue and related symptoms in carnitine-deficient patients with AIDS.
Details: Fatigue is a commonly reported symptom in patients with end stage AIDS. Appropriate treatment can relieve suffering and improve quality of life. The role of progression of the disease, depression, anemia, and poor nutritional status in the development of fatigue is well recognized. However, the impact of micronutrient deficiencies has been minimally explored. AIDS patients are at risk for micronutrient deficiencies because of decreased caloric intake, increased metabolic requirements, and treatment with medications that can interfere with absorption, synthesis, and excretion. Patients with AIDS are particularly likely to be carnitine deficient. Levocarnitine (L-carnitine) is a micronutrient found in meat and dairy products that plays a major role in energy metabolism. Preliminary research has shown that patients with end stage AIDS experienced decreased levels of fatigue after L-carnitine supplementation. This study will evaluate the effectiveness of L-carnitine to treat patients with carnitine deficiency, fatigue, and AIDS. Participants in this study will be randomly assigned to receive either L-carnitine or placebo for 2 weeks. To reduce the possibility of side effects, the doses of L-carnitine and placebo will be titrated over 6 days to the desired study dose. After 2 weeks, participants receiving placebo will be switched over to receive L-carnitine. All participants will continue on L-carnitine for an additional 2 weeks.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - AIDS at Stage IV-C and estimated life expectancy < 6 months - Karnofsky Performance Score > 50 - Clinically significant, persistent fatigue - If undergoing pre-existing treatment for fatigue, must have been on a stable regimen for at least 4 weeks prior to study entry - Concurrent use of epoetin alfa (PROCRIT®) will be allowed if the patient has been on a stable dose of epoetin alfa for at least 60 days prior to study entry Exclusion Criteria: - Severe cardiovascular, pulmonary, or renal function - Hemodialysis - Treatment or replacement therapy with any form of carnitine within 12 months prior to study entry - Known sensitivity to carnitine - Acute illness within 30 days of study entry that in the opinion of the study investigator would interfere with participation - Active drug or alcohol use or dependence - History of any central nervous system disease involving the brain that may put the patient at risk for seizure (e.g., primary or metastatic brain tumor, stroke) or history of seizure - History of dementia, aphasia, or other deficits of cognition or speech/language function
Total Enrollment: 44
Location and Contact Information:
Overall Study Official:
RicardoCruciani, Principal Investigator, Beth Israel Medical Center
Department of Pain Medicine and Palliative Care; Beth Israel Medical Center; First Avenue at 16th Street *Recruiting*
New York City, New York, 10003
United States
Recruiting Ricardo Cruciani 212-420-4748
Additional Information:
Study ID Numbers: 1 R21 NR08295-01;
Study Start Date: November 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00079599
Other Hiv Infections Studies:
1. A Study of a Combination of Four Drugs in Patients with Recent HIV Infection
2. A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children
3. A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients with CD4 <= 500 cells/mm3
4. Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
5. A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
L-Carnitine to Treat Fatigue in AIDS Patients
|
|
|
|
|
|
|
|
